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     The effects of exogenous luteinizing hormone releasing hormone (LH-RH, 5 µg/kg 
body wt) on luteinizing hormone (LH) secretion were investigated in anesthetized male 
dogs pretreated intraventricularly with arginine-vasotocin (AVT, 0.01 µg/kg body wt) 3, 
24 or 48 h previously; the rate of secretion of 17-oxosteroids by the testes in vivo served 
as an index of LH release. The administration of LH-RH into the carotid artery 
resulted in a notable increase in the secretion of testicular 17-oxosteroids. This effect 
of LH-RH was diminished by treatment with AVT 3 or 24 h previously but not affected 
by treatment 48 h earlier. On the other hand, treatment 3 or 24 h previously with AVT 
did not affect the testicular response to i. v. injection of human chorionic gonadotrophin 
(HCG, 5 i . u. /kg body wt). It is thus concluded that in the dog, AVT can inhibit the 
LH releasing effect of LH-RH by acting directly on the anterior pituitary gland even 
when administered into the third ventricle and the effect is relatively long-lasting.
                  INTRODUCTION 
     It has been known that the pineal peptide arginine-vasotocin (AVT)1'7.10> inhibits 
the release of luteinizing hormone (LH) from the anterior pituitary gland2'5'8'9,13) . In 
previous experiments in male dogsls.19>, we have shown that the administration into the 
carotid artery of AVT inhibits the effects of luteinizing hormone releasing hormone 
(LH-RH) on the secretion of LH. The present paper describes observations made on 
adult male dogs for up to 48 h after the administration into the third ventricle of 
AVT ; the concentrations of 17-oxosteroids in the spermatic venous blood were used as 
an index of LH secretion", 17).
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              MATERIALS AND METHODS 
      Adult male mongrel dogs weighing between 9.0 and 16.7 kg were used. The 
operations and experiments were carried out under sodium pentobarbital (Nembutal, 
Abbott Laboratories; 25 mg/kg body wt, i.v.)-induced anesthesia. 
                             Injections of materials 
     Arginine-vasotocin (AVT, Protein Research Foundation ; 0.01 pg/kg body wt in 
0.5 ml 0.9 % saline) was administered stereotaxically into the third ventricle for 1 min 
and control dogs received 0.9% saline only ; after the injection had been completed, the 
animals were removed from the stereotaxic apparatus. Three, 24 or 48 h after this 
injection, luteinizing hormone releasing hormone (LH-RH, Protein Research Founda-
tion ; 5 pg/kg body wt in 1 ml 0.9 % saline) was injected into the left carotid artery 
over a period of 60 s. In other experiments, human chorionic gonadotrophin (HCG ; 
CG-10, Sigma Chemical Company; 5 i.u./kg body wt in 1 ml 0.9 % saline) was 
injected into the left saphenous vein over a period of 15 s instead of LH-RH. The 
completeness of the injection into the third ventricle was in every case confirmed by 
injecting dye. 
                           Spermatic venous cannulation 
     Approximately 2 h before the administration of either LH-RH or HCG, the left 
carotid artery was exposed. The left spermatic vein was then approached through a 
longitudinal incision in the left lumbar area and cannulated15,16> ; since this technique 
permits continuous or intermittent collection of the total venous effluent from the left 
testis, the rate of flow (ml/kg body wt/min) of spermatic venous blood can be estima-
ted from the body weight and the volume of blood collected. 
                         Blood collection and analysis 
     Blood sampling began approximately 1 h after the end of spermatic venous 
cannulation. After control samples of spermatic venous blood had been collected, 
timed spermatic venous blood samples (about 10 ml) were taken for 2 to 6 min periods 
beginning 15, 30, 60, 90 and 120 min after the injection of either LH-RH or HCG. 
Each sample was centrifuged at 4 °C and plasma (3 ml) was analysed for total 17-
oxosteroids using 4-androstene-3, 17-dione as a reference standard 4'161 ; with a micro-
Zimmermann reaction, the lower limit of detection of 17-oxosteroids in the assay was 
30 ng6). The rate of secretion of 17-oxosteroids from one testis was expressed as ng/kg 
body wt/min calculated from the concentration (ng/ml) of 17-oxosteroids and the rate 
of flow (ml/kg body wt/min) of spermatic venous plasma. Finally, the secretions of 
17-oxosteroids at various times after the injection of LH-RH or HCG in dogs with and 
without AVT were compared ; Student's t-test was used to detect differences between 
means, and a P value greater than 0.05 was considered not significant.
                     RESULTS 
                          AVT and LH-RH 
     Results of LH-RH administration on the secretion of testicular 17-oxosteroids in 
untreated and AVT-treated dogs are compared in Fig. 1. In dogs which had received 
control saline injections 3, 24 or 48 h previously, the administration of LH-RH consi-
       Time(min) before and after LH-RH injection 
Fig. 1. Secretion of 17-oxosteroids by one testis in response to intracarotid injection 
       of luteinizing hormone releasing hormone (LH-RH, 5 fig/kg body wt) in 
       adult male dogs pretreated with arginine-vasotocin(AVT; S, 0.01 rig/kg body 
       wt) or isotonic saline (0) into the third ventricle 3 (a), 24 (b) or 48 h (c) 
        previously. Each point represents the mean ± SEM of results from five
        dogs; arrows indicate the time of injection of LH-RH. *P <0.05; **P< 
        0.01: significantly different from the corresponding value when LH-RH 
       was given without AVT (Student's t-test).
derably increased the secretion of testicular 17-oxosteroids and these responses were of 
almost the same size (Fig. 1 a, b and c). When LH-RH was injected into dogs that 
were treated into the third ventricle with AVT 3 h earlier, the response to LH-RH on 
the secretion of testicular 17-oxosteroids tended to be diminished and the difference 
between untreated and AVT-treated dogs in response 60 min after the injection was 
significant (P<0.01) (Fig. 1a). In dogs treated with AVT 24 h previously, the admi-
nistration of LH-RH caused a considerably lesser increase in the secretion of testicular 
steroids and the responses 15, 30 and 60 min after the injection of LH-RH were signifi-
cantly (P<0.05, P<0.01 and P<0.05, respectively) less than those obtained in dogs not 
pretreated with AVT (Fig. 1b). In dogs treated with AVT 48 h earlier, the testicular 
response to LH-RH administration was not significantly different from that obtained in 
dogs not pretreated with AVT (Fig. 1c). 
                          AVT and HCG
     In experiment performed to study the effect of AVT, injected into the third 
ventricle 3 or 24 h previously, on the HCG-induced secretion of testicular 17-oxoste-
roids, no modification of the response in the secretion of testicular 17-oxosteroids was 
observed (Table 1). 
   Table 1. Effects of i.v. injection of human chorionic gonadotrophin (HCG, 5 i.u./kg 
            body wt) on testicular 17-oxosteroid secretion in adult male dogs pretreated with 
           arginine-vasotocin (AVT, 0.01 ug/kg body wt) or isotonic saline into the third
           ventricle 3 or 24 h previously (means ± SEM of results from four dogs)
                                 17-Oxosteroid secretion by one testis (ng/kg/min) 
      Pretreatment 
                       -20 min -10 min 15 min 30 min 60 min 90 min 120 min 
3 h after treatment with: 
       isotonic saline 2.3±1.1 1.8±1.1 12.3±3.7 53.6±6.3 47.3±5.2 52.8±5.7 63.2±7.4 
       AVT 1.1±0.8 1.4±0.9 16.9±2.8 46.7±8.3 41.3±8.2 60.9±9.3 58.6±8.1 
24 h after treatment with: 
       isotonic saline 1.9±0.9 2.6±1.8 18.3±3.1 48.8±5.6 44.7±6.2 51.2±7.1 57.1±6.6 
      AVT 1.2±0.7 0.8±0.5 13.9±4.6 45.1±7.1 41.8±7.4 45.4±8.2 55.3±9.6
                    DISCUSSION 
     The results presented in Fig. 1 show that in the dog, the response of testicular 
17-oxosteroid secretion to LH-RH can be suppressed by the previous administration 
into the third ventricle of AVT. It may have been produced by the action of AVT on 
the testes and/or the anterior pituitary gland. There is evidence that AVT exerts a 
direct inhibitory effect on the gonads' In our previous study in male dogs19 , 
AVT inhibited the testicular response to HCG when administered i.v. at the same
time, but it was not shown when AVT was administered i.v. 3 h earlier. In addition, 
there was the ineffectiveness of AVT on the HCG responses when administered into 
the carotid artery 3 h previously. In the present experiment too, treatment 3 or 24 h 
previously with AVT into the third ventricle did not affect the testicular response to 
the low dose of HCG. These findings indicate that the inhibition of testicular steroid 
secretion observed in this study may have been due to a direct action of AVT on the 
anterior pituitary gland and not on the testes. It is therefore probable that AVT is 
able to inhibit the LH-releasing effect of LH-RH by acting directly on the anterior 
pituitary gland even when administered into the third ventricle. The effect appears 
to be relatively long-lasting, since the time allowed to show the anterior pituitary-
depressing effect of intraventricular AVT at the dose used was 24 h or so. 
      In contrast to our observations in dogs, evidence for the anterior pituitary gland 
as one of the sites of inhibition has not been obtained from experiments in vivo2,8 9 and 
in vitro' 4) by most investigators using rats. These results in rats are difficult to inter-
pret because of differences in species and experimental design; in addition, the use of 
rats anesthetized with urethane9), whereas other groups were handled without anesthesia, 
makes comparison with our data difficult. Recently, Dr. M. K. Vaughan and co-
workers, the University of Texas Health Center at San Antonio, U. S. A., observed a 
stimulatory effect of AVT on the release of LH induced by LH-RH in urethane-
anesthetized rats, but they repeated the experiment in unanesthetized male rats and 
found that AVT inhibited the effects of LH-RH on LH secretion (unpublished data, 
personal communication). 
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